Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: A meta-analysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 5, 2015, Pages 391-397

  Yu, Xiaoyong ^a   Gan, Liangying ^b   Wang, Zhaohui ^c   Dong, Bao ^b   Chen, Xiaohong ^a  

^a Traditional Chinese Hospital of Shanxi   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Acute kidney injury; Meta analysis; Multiple myeloma; Plasmapheresis

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; VINCRISTINE;

ACUTE KIDNEY FAILURE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DIALYSIS; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PLASMAPHERESIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; ACUTE KIDNEY INJURY; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; COMPLICATION; MORTALITY; ODDS RATIO; RENAL REPLACEMENT THERAPY; RISK; RISK FACTOR; TIME; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CHI-SQUARE DISTRIBUTION; HUMANS; MULTIPLE MYELOMA; ODDS RATIO; PLASMAPHERESIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84936764698     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202245     Document Type: Article

References (25)

1. Smith D, Yong K. Multiple myeloma. BMJ. 2013; 346 (jun26 2): f3863 CrossRef PubMed
2. Chapdelaine I, Madore F. Plasmapheresis in myeloma cast nephropathy. Clin Nephrol. 2013; 79: 72-77. CrossRef PubMed
3. Pozzi C, Pasquali S, Donini U, Casanova S, Banfi G, Tiraboschi G, Furci L, Porri MT, Ravelli M, Lupo A, et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italien Renal Immunopathology Group. Clin Nephrol. 1987; 28: 1-9. PubMed
4. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003; 78: 21-33. CrossRef PubMed
5. Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med. 1990; 150: 1693-1695. CrossRef PubMed
6. Wirk B. Renal failure in multiple myeloma: a medical emergency. Bone Marrow Transplant. 2011; 46: 771-783. CrossRef PubMed
7. Leung N, Behrens J. Current approach to diagnosis and management of acute renal failure in myeloma patients. Adv Chronic Kidney Dis. 2012; 19: 297-302. CrossRef PubMed
8. Batuman V. The pathogenesis of acute kidney impairment in patients with multiple myeloma. Adv Chronic Kidney Dis. 2012; 19: 282-286. CrossRef PubMed
9. Feest TG, Burge PS, Cohen SL. Successful treatment of myeloma kidney by diuresis and plasmaphoresis. BMJ. 1976; 1: 503-504. CrossRef PubMed
10. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN; Canadian Apheresis Group. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005; 143: 777-784. CrossRef PubMed
11. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med. 1990; 150: 863-869. CrossRef PubMed
12. Misiani R, Remuzzi G, Bertani T, Licini R, Levoni P, Crippa A, Mecca G. Plasmapheresis in the treatment of acute renal failure in multiple myeloma. Am J Med. 1979; 66: 684-688. CrossRef PubMed
13. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int. 1988; 33: 1175-1180. CrossRef PubMed
14. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008; 73: 1282-1288. Cross-Ref PubMed
15. Moist L, Nesrallah G, Kortas C, Espirtu E, Ostbye T, Clark WF. Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series. Am J Nephrol. 1999; 19: 45-50. CrossRef PubMed
16. Gupta D, Bachegowda L, Phadke G, Boren S, Johnson D, Misra M. Role of plasmapheresis in the management of myeloma kidney: a systematic review. Hemodial Int. 2010; 14: 355-363. Cross-Ref PubMed
17. Cserti C, Haspel R, Stowell C, Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion. 2007; 47: 511-514. CrossRef PubMed
18. Leung N. Plasma exchange in multiple myeloma. Ann Intern Med. 2006; 144: 455, author reply 455. CrossRef PubMed
19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996; 17: 1-12. CrossRef PubMed
20. Pasquali S, Cagnoli L, Rovinetti C, Rigotti A, Zucchelli P. Plasma exchange therapy in rapidly progressive renal failure due to multiple myeloma. Int J Artif Organs. 1985; 8 (Suppl 2): 27-30. PubMed
21. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007; 18: 886-895. CrossRef PubMed
22. Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, Cockwell P. Serum freelight chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs. 2008; 32: 910-917. CrossRef PubMed
23. Schmitt S, Bertsch U, Goldschmidt H. Experiences with bortezomib in multiple myeloma - from Phase II studies to daily practice. Int J Clin Pharm Ther. 2010; 48: 494-496. PubMed
24. Dahal K, Shastri S, Narayanasami U, Bijol V, Rider K, Strom JA, Jaber BL. Recovery of kidney function following delayed use of Theralite™ dialyzer in a patient with myeloma cast nephropathy. Clin Nephrol. 2013; 79: 318-322. CrossRef PubMed
25. Pillon L, Sweeting RS, Arora A, Notkin A, Ballard HS, Wieczorek RL, Leung N. Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis? Kidney Int. 2008; 74: 956-961. CrossRef PubMed